Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
2023-503387-16-00Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Seagen Inc. Primary endpoint: Complete response (CR) rate at end of treatment (EOT). Started Oct 2023; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2023-503387-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503387-16-00.